[Influencing of the PSA concentration in serum by physical exercise (especially bicycle riding)].
BACKGROUND
Sports and in particular cycling are assumed to influence PSA in serum. Controversial scientific results were the motivation to examine the influence of a standardized test on a cycling ergometer and a treadmill on PSA concentrations in elderly men with elevated PSA levels and a benign prostate hyperplasia.


METHODS
A total of 21 male volunteers (aged 61 ± 5 years, tPSA 7.7 ± 3.0 ng/ml and benign prostate hyperplasia with a prostate volume of 54 ± 18 ml) performed a 1 h cycling test on a cycling ergometer. A subgroup of 15 volunteers also performed a 1 h test on a treadmill. Blood samples were drawn before and several times after the cycling stress test up to 7 days afterwards (up to 120 min after the test on the treadmill) to determine total PSA (tPSA), complexed PSA (cPSA) and free PSA (fPSA).


RESULTS
The average increase in tPSA of 1.9 ± 1.7 ng/ml (25%) after the cycling exercise test was significant. After the treadmill exercise the PSA increase was not as high, but with 1.0 ± 1.0 ng/ml (12%) was also significant. On average the levels of PSA returned to the basic level 48 h after the cycling test, but in individual cases it took longer. fPSA showed the most noticeable increase after cycling with 92% on average. There was no correlation between increase in PSA and prostate volume.


CONCLUSIONS
Men should abstain from physical exercise, especially from cycling for several days and at least for 24 h before PSA measurements are carried out. This applies to patients with elevated PSA levels (>4 ng/ml) when a PSA follow-up is being carried out.
Institut für Sport- und Präventivmedizin, Universität des Saarlandes, Campus, Gebäude B8.2, 66123 Saarbrücken, Deutschland. w.kindermann@mx.uni-saarland.de
W
W
Kindermann
V
V
Lehmann
M
M
Herrmann
T
T
Loch
D001642:Bicycling; D015444:Exercise; D006801:Humans; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000503:physiopathology*
D017430:Prostate-Specific Antigen
Arch Pathol Lab Med. 2003 Mar;127(3):345-8
12653581
N Engl J Med. 2009 Mar 26;360(13):1310-9
19297565
Urologe A. 2004 Nov;43(11):1377-84
15517143
N Engl J Med. 2009 Mar 26;360(13):1320-8
19297566
Int J Sports Med. 2005 Jan-Feb;26(1):79-81
15643540
Ann Intern Med. 1993 Nov 1;119(9):956
7692783
Lancet Oncol. 2010 Aug;11(8):725-32
20598634
J Urol. 1997 May;157(5):1744-7
9112518
Urology. 1999 Nov;54(5):857-61
10565747
J Int Med Res. 2004 Nov-Dec;32(6):583-9
15587752
J Urol. 1996 Jul;156(1):103-5
8648767
J Urol. 1993 Sep;150(3):893-4
7688434
J Urol. 1998 Apr;159(4):1234-7
9507843
Urology. 2009 Dec;74(6):1325-30
19781750
Prostate Suppl. 1996;7:35-9
8950362
J Urol. 1997 Jan;157(1):195-8
8976249
J Urol. 1994 Mar;151(3):700
7508526
Clin Chem. 1997 Aug;43(8 Pt 1):1465-6
9267335
Urology. 2003 Jun;61(6):1177-80
12809893
Urology. 1995 May;45(5):729-44
7538236
Clin Chem. 2005 Aug;51(8):1342-51
15961552
Arch Fam Med. 1997 Sep-Oct;6(5):500-2
9305697
World J Urol. 2004 Nov;22(5):357-60
15672278
Int Urol Nephrol. 2006;38(1):161-2
16502074
Clin Chem. 1996 May;42(5):691-5
8653893
J Appl Physiol. 1974 Aug;37(2):247-8
4850854
Clin Chem Lab Med. 2004 Mar;42(3):347-9
15080570